During the Goldman Sachs 47th Annual Global Healthcare Conference, Geron Corporation (GERN) CEO Harout Semerjian presented an overview of the company's current status and future prospects. Geron has transitioned to a commercial stage following the approval of its lead product, RYTELO, which is designed to assist patients with low-risk myelodysplastic syndromes (MDS). This approval marks a significant milestone for Geron, which has faced many challenges and strategic shifts over the years. Semerjian noted that RYTELO is the first telomerase inhibitor available on the market for this indication. Additionally, the company is conducting a Phase III trial for RYTELO in patients with myelofibrosis who have relapsed or are refractory to RUX. As Geron continues to grow, it aims to enhance its international presence and support more patients globally. Semerjian expressed optimism about the company's potential to deliver further advancements in patient care as data from ongoing trials matures.